Selonabant - Anebulo Pharmaceuticals
Alternative Names: ANEB 001; V-24343Latest Information Update: 01 Oct 2024
At a glance
- Originator Vernalis
- Developer Anebulo Pharmaceuticals; Vernalis
- Class Drug withdrawal therapies; Obesity therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Substance-related disorders
- Discontinued Obesity
Most Recent Events
- 25 Sep 2024 Anebulo Pharmaceuticals plans a clinical study (In volunteer) in the first half of 2025
- 22 Jul 2024 Anebulo Pharmaceuticals has patent protection for composition of matter of crystalline form of Selonabant and its methods of use in USA
- 22 Jul 2024 Anebulo Pharmaceuticals has patents pending for methods of use of Selonabant and delivery systems